NEW YORK (GenomeWeb News) – SAIC-Frederick and Roche Applied Science will collaborate to test Roche's sequence capture and sequencing technologies for use in research projects for the National Cancer Institute, Roche Diagnostics said today.
A contractor for NCI, SAIC-Frederick will use the NimbleGen Sequence Capture technology, along with the Genome Sequencer FLX from Roche's 454 Life Sciences business, to conduct targeted re-sequencing for cancer genomics studies.
Under NCI's Advanced Technology Partnerships Initiative, SAIC-Frederick will assess how Roche NimbleGen's SeqCap EZ system works to capture specific regions of the genome of a cancer research sample. That captured DNA will then be re-sequenced using the FLX system in an effort to identify genetic variants that contribute to cancer outcomes, Roche said.
"Our intent is to implement Roche NimbleGen's solution-based sequence capture technology, SeqCap EZ, to rapidly advance our next-generation sequencing projects and in turn, increase our knowledge of cancer genetics," said Joseph Boland, who is dedicated scientific operations manager of SAIC-Frederick's Core Genotyping Facility.
Financial terms of the agreement were not released.